Information Provided By:
Fly News Breaks for December 19, 2019
CRK, MGNX, REAL, MMX, TACT
Dec 19, 2019 | 10:09 EDT
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Comstock Resources (CRK) initiated with a Neutral at MKM Partners. 2. MacroGenics (MGNX) initiated with an Overweight at Cantor Fitzgerald. 3. RealReal (REAL) initiated with a Buy at Needham. 4. Maverix Metals (MMX) initiated with an Outperformer at CIBC. 5. Transact Technologies (TACT) resumed with a Buy at B. Riley FBR. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
News For CRK;MGNX;REAL;MMX;TACT From the Last 2 Days
MGNX
Jun 5, 2020 | 07:32 EDT
MacroGenics announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to margetuximab, an investigational, Fc-engineered monoclonal antibody targeting HER2 for the treatment of gastric and gastroesophageal junction cancer. Margetuximab is currently being evaluated in the Phase 2/3 MAHOGANY clinical trial in combination with checkpoint inhibition, with or without chemotherapy, as a potential first-line treatment for patients with HER2-positive gastric cancer or gastroesophageal junction cancer. The MAHOGANY study is based on results from an ongoing Phase 2 study of margetuximab plus pembrolizumab, an anti-PD-1 monoclonal antibody, for patients with advanced HER2-positive GC or GEJ cancer who have previously been treated with chemotherapy and trastuzumab in the metastatic setting. Data were presented at the European Society for Medical Oncology Annual Congress in September 2019.